Recruiting Clinical Trials

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

By April 24, 2017 No Comments



Estimated Enrollment: 600

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: CA209-743|2016-001859-43

Study First Received: August 31, 2016

Last Updated: April 17, 2017

Estimated Primary Completion Date: October 2020


Primary Outcome Measures:

Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Composite correlation of PD-L1 expression level and efficacy

Sponsors and Collaborators:

Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd

Website Link:

Leave a Reply

Call Now ButtonCall Now